Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

Mahsa Ghajarzadeh¹, Omid Mirmosayyeb², Mahdi Barzegar³, Nasim Nehzat⁴, Saeed Vaheb⁵, Vahid Shaygannejad⁶, Amir-Hadi Maghzi⁷

Affiliations

¹ Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran.
² Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
³ Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁴ Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁵ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁶ Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: shaygannejad@med.mui.ac.ir.
⁷ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 32464586
PMCID: PMC7245286
DOI: 10.1016/j.msard.2020.102222

Case Reports

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

Mahsa Ghajarzadeh et al. Mult Scler Relat Disord. 2020 Aug.

. 2020 Aug:43:102222.

doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.

Authors

Mahsa Ghajarzadeh¹, Omid Mirmosayyeb², Mahdi Barzegar³, Nasim Nehzat⁴, Saeed Vaheb⁵, Vahid Shaygannejad⁶, Amir-Hadi Maghzi⁷

Affiliations

¹ Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran.
² Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
³ Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁴ Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁵ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁶ Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: shaygannejad@med.mui.ac.ir.
⁷ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 32464586
PMCID: PMC7245286
DOI: 10.1016/j.msard.2020.102222

No abstract available

Keywords: COVID-19; Multiple sclerosis; Ocrelizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interests AHM was supported by a clinician-scientist development fellowship by National MS Society and American Brain Foundation. The authors have no other relevant conflicts of interest.

References

1. Giovannoni G. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult. Scler. Relat. Disord. 2020;41 - PMC - PubMed
1. Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult. Scler. Relat. Disord. 2020;42 - PMC - PubMed
1. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult. Scler. Relat. Disord. 2020;0(0) - PMC - PubMed
1. Novi G, Mikulska M, Briano F. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult. Scler. Relat. Disord. 2020;42 - PMC - PubMed
1. Suwanwongse K, Shabarek N. Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab. Mult. Scler. Relat. Disord. 2020;0(0) - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

Affiliations

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

Authors

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources